Myriad Genetics: Vectra Report

Myriad Genetics has enhanced its test report for Vectra, a multi-biomarker, molecular blood test for measuring inflammatory disease activity in rheumatoid arthritis patients. The new report provides an estimate of each patient's one-year risk of rapid radiographic progression, factoring in age, gender, and adiposity. Previously, the company reported a measure of patients' current RA inflammation, but the added information in the latest version of the report can inform them of the future risk of joint damage and "further guide [their] medical management decisons," Mark Verratti, president of Myriad Neuroscience and Myriad Autoimmune, said in a statement.